Live Quote · NASDAQIOVAHealthcare · Biotechnology

Iovance Biotherapeutics, Inc.

$4.31▲ 8.56%(+$0.34)

TickerSpark Score

73/100

▌ Solid

53

Valuation

40

Profitability

90

Growth

84

Health

100

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IOVA research report →

52-Week Range67% of range

Low

$1.68

Current

$4.31

High

$5.63

Company Overviewwww.iovance.com

About the company

Iovance Biotherapeutics, Inc. , a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells.

CEO: Frederick G. Vogt
IPO: 2010
Employees: 838
HQ: San Carlos, CA, US

Price Chart

+146.29% · this period

Valuation

Market Cap: $1.54B
P/E: -4.68
P/S: 5.40
P/B: 2.50
EV/EBITDA: -4.33
Div Yield: 0.00%

Profitability

Gross Margin: 114.51%
Op Margin: -127.16%
Net Margin: -123.90%
ROE: -50.17%
ROIC: -45.27%

Growth & Income

Revenue: $263.50M · 60.60%
Net Income: $-390,978,000 · -5.05%
EPS: $-1.09 · 14.84%
Op Income: $-403,356,000
FCF YoY: 7.64%

Performance & Tape

52W High: $5.63
52W Low: $1.68
50D MA: $3.86
200D MA: $3.05
Beta: 0.69
Avg Volume: 15.05M

Get TickerSpark's AI analysis on IOVA

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

Date	Insider	Role	Type	Shares	Value
Jun 16, 26	WEISER MICHAEL	director	other	90,316	$0
Jun 16, 26	Dukes Iain D.	director	other	180,632	$0
Jun 16, 26	Countouriotis Athena	director	other	90,316	$0
Jun 16, 26	Maynard Ryan D	director	other	90,316	$0
Jun 16, 26	Puri Raj K.	officer: Chief Regulatory Officer	other	15,000	$0
Jun 5, 26	Vogt Frederick G	director, officer: Interim CEO & General Counsel	other	15,625	$0
Jun 5, 26	Vogt Frederick G	director, officer: Interim CEO & General Counsel	other	6,638	$28.08K
Jun 5, 26	Vogt Frederick G	director, officer: Interim CEO & General Counsel	other	15,625	$0
Jun 5, 26	GRAF FINCKENSTEIN FRIEDRICH	officer: Chief Medical Officer	other	7,813	$0
Jun 5, 26	GRAF FINCKENSTEIN FRIEDRICH	officer: Chief Medical Officer	other	3,976	$16.82K

Coverage · IOVA

Our IOVA coverage

Recent articles, reports, and earnings notes.

View all →

IPO

What to Watch as SL Science Holding Limited Prices on Nasdaq

SL Science Holding Limited Ordinary Shares (SLBT) is expected to list on Nasdaq on 2026-06-15, but the price range has not been disclosed. This is a de-SPAC listing rather than a traditional IPO, so the key question is whether the market gives credit to a small-revenue biotech platform with a very large headline valuation.